Overview

Safety and Efficacy Study of Prosaptide to Treat Neuropathic Pain in HIV-Positive Patients

Status:
Terminated
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo-controlled, parallel groups study to determine whether prosptide is effective in relieving pain in patients who have sensory neuropathic pain related to their HIV infection or the drugs used to treat it.
Phase:
Phase 2
Details
Lead Sponsor:
Savient Pharmaceuticals
Collaborator:
Neurologic AIDS Research Consortium (NARC)